Immunomodulatory effects of Fucoidan (seaweed extract) in recreationally active adults
Not Applicable
- Conditions
- Immune CompetenceInflammatory and Immune System - Normal development and function of the immune system
- Registration Number
- ACTRN12621000872831
- Lead Sponsor
- niversity of Canberra
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Male
- Target Recruitment
- 15
Inclusion Criteria
Be male;
Be aged between 18-45 years;
Have a 12 month history of regular physical activity of a minimum of 30 minutes of moderate intensity exercise per day, or the equivalent of 3.5 hours per week;
Exclusion Criteria
Have no history of gastrointestinal disease (IBD, IBS etc), asthma, diabetes,
renal disease, cardiovascular disease, arthritis or use immune-modulating medications
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways does Fucoidan modulate in immune cell signaling for recreationally active adults?
How does Fucoidan supplementation compare to standard-of-care immune-boosting agents in biomarker profiles?
Which immune biomarkers (e.g., cytokine levels, NK cell activity) predict response to Fucoidan in ACTRN12621000872831?
What are the safety profiles and management strategies for Fucoidan-induced immune-related adverse events?
What combination therapies with Fucoidan (e.g., TLR4 agonists, NF-κB inhibitors) enhance immunomodulatory effects in healthy populations?